Previous 10 | Next 10 |
2023-08-15 16:20:35 ET More on Reata Pharmaceuticals Biogen's Bold $7.3B Acquisition Of Reata: Analyzing The Impact On Investors Reata: FDA Approval Of SKYCLARYS Isn't Only Driver Moving Forward Reata Pharmaceuticals: 'Buy' Following Skyclarys Delay And Bardoxolone D...
2023-08-14 07:00:00 ET Summary Biotech stocks faced challenges in the first half of the year, with the Nasdaq Biotechnology Index losing 3%, compared to strong advances in the broader market. The direction of the 10-year bond yield has become a key predictor of biotech industry pe...
2023-08-13 08:02:00 ET More on Cisco, Deere, etc. Compare metrics for CSCO to DE, HD, SNDL, TGT, WMT Walmart: The Bottom Could Fall Out If Inflation Levels Continue To Fall Home Depot: Long-Term Winner, With Room To Run Target estimates lowered at Barclays ah...
2023-08-11 14:23:56 ET Summary Biogen focuses on neurological therapies, recently acquired Reata Pharmaceuticals, and shows mixed financial performance. Q2 2023 earnings reveal revenue decline, but strong liquidity; Alzheimer's treatments are key growth areas with notable developm...
NEW YORK, NY / ACCESSWIRE / July 31, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Reata Pharmaceuticals, Inc. ...
NEW YORK, NY / ACCESSWIRE / July 31, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Sculptor Capital Management Inc. (NYSE:S...
2023-07-31 06:13:00 ET Shares of Reata Pharmaceuticals (NASDAQ: RETA) recently jumped about 54% higher in a single trading session. This biotech stock was already way up this year thanks to the recent approval of its first drug, Skyclaris, in February. A juicy buyout offer with ...
2023-07-28 17:20:10 ET Summary Biogen Inc. has announced plans to acquire Reata Pharmaceuticals, Inc. for $7.3 billion, validating the potential of Skyclarys. Skyclarys, the sole FDA-approved treatment for Friedreich's ataxia, has considerable market potential, justifying the acqu...
2023-07-28 13:22:08 ET Larimar Therapeutics ( NASDAQ: LRMR ), which has a candidate in phase 2 for Friedreich's Ataxia ("FA"), is up 22% in Friday afternoon trading, a beneficiary of Biogen's ( BIIB ) announcement to acquire Reata Pharmaceuticals ( RETA ) for more th...
2023-07-28 12:49:57 ET Gainers: Unique Fabricating ( UFAB ) +74% . Reata Pharmaceuticals ( RETA ) +52% . INVO Bioscience ( INVO ) +45% . Bluejay Diagnostics ( BJDX ) +44% . View ( VIEW ) +40% . iClick Interactive Asia Group L...
News, Short Squeeze, Breakout and More Instantly...
Reata Pharmaceuticals Inc. Company Name:
RETA Stock Symbol:
NASDAQ Market:
Reata Pharmaceuticals Inc. Website:
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2...
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023